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Abstract
Background: Serological tests for IgM and IgG are routinely used in clinical laboratories for the rapid diagnosis of dengue
and can differentiate between primary and secondary infections. Dengue virus non-structural protein 1 (NS1) has been
identified as an early marker for acute dengue, and is typically present between days 1–9 post-onset of illness but following
seroconversion it can be difficult to detect in serum.
Aims: To evaluate the performance of a newly developed PanbioH Dengue Early Rapid test for NS1 and determine if it can
improve diagnostic sensitivity when used in combination with a commercial IgM/IgG rapid test.
Methodology: The clinical performance of the Dengue Early Rapid was evaluated in a retrospective study in Vietnam with
198 acute laboratory-confirmed positive and 100 negative samples. The performance of the Dengue Early Rapid in
combination with the IgM/IgG Rapid test was also evaluated in Malaysia with 263 laboratory-confirmed positive and 30
negative samples.
Key Results: In Vietnam the sensitivity and specificity of the test was 69.2% (95% CI: 62.8% to 75.6%) and 96% (95% CI:
92.2% to 99.8) respectively. In Malaysia the performance was similar with 68.9% sensitivity (95% CI: 61.8% to 76.1%) and
96.7% specificity (95% CI: 82.8% to 99.9%) compared to RT-PCR. Importantly, when the Dengue Early Rapid test was used in
combination with the IgM/IgG test the sensitivity increased to 93.0%. When the two tests were compared at each day post-
onset of illness there was clear differentiation between the antigen and antibody markers.
Conclusions: This study highlights that using dengue NS1 antigen detection in combination with anti-glycoprotein E IgM
and IgG serology can significantly increase the sensitivity of acute dengue diagnosis and extends the possible window of
detection to include very early acute samples and enhances the clinical utility of rapid immunochromatographic testing for
dengue.
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Introduction
Dengue is a significant public health threat, with estimates of
50 to 100 million cases per year and around 3 billion people at
risk of infection [1]. There have now been epidemics reported in
over 100 countries and they appear to be occurring more
frequently [2]. The global burden from dengue infections is likely
to be much higher than current prevalence data suggests with
only 10% of symptomatic cases believed to be reported [3].
Dengue is a febrile illness caused by the dengue virus, a group of
single stranded RNA viruses belonging to the Flaviviridae family
and Flavivirus genus. The four serotypes (DENV1-4) of dengue
virus are transmitted to humans primarily via Aedes aegypti
mosquitoes. Infection can result in a broad spectrum of disease
syndromes ranging from an asymptomatic or mild infection,
classical dengue fever (DF), to the potentially fatal dengue
haemorrhagic fever (DHF) and dengue shock syndrome (DSS)
[4]. Classical DF is characterised by a sudden onset of fever with
a combination of severe headache, retro-orbital pain, myalgia,
arthralgia, rash, nausea and vomiting. DHF and DSS are also
www.plosntds.org 1 June 2011 | Volume 5 | Issue 6 | e1199characterised by increased vascular permeability, thrombocyto-
penia and haemorrhaging with haemoconcentration being a key
indicator in differentiating it from DF [5].
A primary infection confers lifelong protective immunity against
the infecting serotype but not cross-protection against any of the
other three serotypes [6]. A risk factor for DHF and DSS is a
secondary infection with a heterologous serotype. Other risk
factors include age, duration between dengue infections, ethnicity
as well as the serotype and genotype of the infecting virus [7].
There is currently no licensed dengue vaccine available and the
only means of prevention is through surveillance and vector
control. There is also no effective anti-viral therapeutic on the
market and supportive therapy such as fluid replacement is the
only treatment for severe forms of the disease. An early and
accurate laboratory diagnosis of dengue could assist clinical
management. Virus isolation coupled with immunofluorescence
is an effective technique for early diagnosis of dengue. However, it
is time-consuming and due to the short duration of viraemia is
only sensitive for samples taken up to 5 days post-onset of infection
[8]. Real time RT-PCR has also proven to be a highly sensitive
and powerful alternative to virus isolation as it has a wider window
of detection and allows for both quantitation of viral loads and
serotyping [8]. However, molecular techniques such as PCR
require specialised equipment, and there has been little progress in
the standardisation of protocols, which has limited their utility in
lower socio-economic countries where there is a need for simple
and affordable testing.
Relatively inexpensive serological tests, and in particular rapid
point-of-care devices, have become more widely used in endemic
settings. Primary dengue infection is characterised by the presence
of significant or rising levels of IgM 3–5 days after the onset of
infection, which can persist for 1–3 months, whereas secondary
infection is characterised by elevated IgG levels, reaching a peak
window of detection at 6–15 days after onset of symptoms and may
also be accompanied by IgM [5,9]. The Dengue Duo Cassette is
designed to detectIgM antibodies to dengue,as well as elevated IgG
titers that are indicative of a secondary infection. The assay is
intentionally designed to not detect low level IgG antibodies from
past exposure, which is common in individuals from endemic
regions. In the last decade, dengue non-structural protein 1 (NS1)
has been identified as a useful early serum marker for primary and
secondary dengue infections, and is typically present between days
1–9 after onset of clinical signs, with a peak from days 3–5 [1,2,10–
13]. The Dengue Early Rapid is a 15-minute immunochromato-
graphic test (ICT) designed for the qualitative detection of dengue
NS1 antigen in human serum. Although not as sensitive as PCR or
ELISA, ICTs are quick and require only a minimum of technical
expertise to perform. Here, we report on the clinical performance of
a new commercial dengue NS1 detection test, evaluated both alone
and in combination with a dengue IgM and IgG rapid test, at two
separate study sites in Southeast Asia.
Methods
Affinity and specificity of anti-NS1 monoclonal antibodies
used in assay development
Anti-Dengue NS1 monoclonal antibodies (Ab1, Ab2 and Ab3)
were generated as part of a previous ARC Linkage grant between
Alere, Australia and the University of Queensland (ARC
LP0668437). Interaction specificities and affinities were deter-
mined using a surface plasmon resonance (SPR) biosensor. The
SPR assay also allowed for the determination of interaction
kinetics. All reagents and sensor chips were purchased from GE
Healthcare unless otherwise indicated. Recombinant DENV1,
DENV3 and DENV4 NS1 were provided by Alere Inc. (Biosite,
U.S.A). Recombinant DENV2 NS1 was supplied by Hawaii
Biotech (U.S.A).
SPR experiments were run on a Biacore T100 instrument (GE).
Binding kinetics of anti-Dengue NS1 antibodies were measured at
25uC using a CM5 sensor chip. An antibody-based capture
method [14] was used to capture the anti-Dengue NS1 mAbs. In
brief, an anti-mouse capture kit (BR-1008-38) and an amine
coupling kit (BR-1000-50) were used to immobilize approximately
12,000 RU of anti-mouse IgG. Following immobilization, 5 mLo f
10 nM anti-Dengue NS1 mAbs were injected over flow cell 2 (Fc2)
at a flow rate of 5 mL/min (leading to 50–70 RU of immobilised
material), with flow cell 1 (Fc1) used as an un-derivatised reference.
In order to investigate the binding kinetics of anti-NS1 mAbs, a
kinetic titration (single cycle kinetics) method was utilised [15].
This method involved injecting an analyte concentration series in
one single cycle without regeneration steps. Dengue NS1 antigens
were prepared in a 3-fold dilution series in HBS-EP running buffer
(10 mM HEPES pH 7.4, 300 mM NaCl, 3 mM EDTA and
0.005% Surfactant P20) at a concentration range of 1000 nM to
12.3 nM. The concentration series of each antigen was then
injected sequentially in order of increasing concentration over
both Fc1 and Fc2 at a flow rate of 30 mL/min for 3 min within one
single cycle, with a dissociation phase monitored for 30 min. The
sensor surface was regenerated between cycles with 10 mM
glycine-HCl pH 1.7 for 40 seconds at a flow rate of 30 mL/min.
Each analysis was repeated at least three times. Mass transport
limitation of binding was determined to be negligible as the
observed binding rate (kobs) of antigen at a range of flow rates was
found to vary by less than 5%.
Data analysis was carried out using Biacore T100 Evaluation
software 2.0 (GE). The association rate constants (ka) and
dissociation rate constants (kd) were determined by the evaluation
of the single cycle kinetc sensorgrams, and the equilibrium
disassociation constants (KD) were derived from the ratio kd/ka.
During the kinetic analysis, a 1:1 binding model was applied
preferentially. This model was sufficient to accurately describe the
binding data when an extremely low level of captured antibody
Author Summary
Dengue is a serious public health concern with around 3
billion people at risk of infection. Severe forms of the
infection can be fatal and with no licensed vaccine or
effective therapeutic currently available, early detection is
important to assist with the clinical management of
symptoms. Isolation of the virus and the detection of viral
RNA using RT-PCR are commonly used methods for early
diagnosis but are time-consuming, expensive and require
skilled operation. Rapid immunochromatographic tests
(ICT) are relatively simple, inexpensive and easy to perform
at or near the point of care. Here, we report on the clinical
performance of a new rapid ICT for the non-structural
protein 1 (NS1) of dengue virus, a marker of acute
infection. At two clinical study sites, NS1 was detected in
60–70% of laboratory-confirmed dengue cases and spec-
ificity of the test was .95%. We have also shown that a
combined testing approach for both circulating NS1
antigen and antibody responses to the glycoprotein E of
the virus can significantly improve diagnostic sensitivity
compared to the detection of NS1 alone. Importantly, the
combined antigen and antibody testing approach also
provides an expanded window of detection from as early
as day 1 post-onset of illness.
Combined Approach to Enhance Dengue Rapid Test
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(second order) binding kinetics was observed, and a bivalent
analyte binding analysis model was applied to better fit the kinetic
parameters (data not shown).
Analytical sensitivity of Dengue Early Rapid antigen test
The theoretical limits of detection for each dengue NS1
serotype were determined using both recombinant and native
antigen preparations. A serial two-fold dilution series of each
recombinant NS1 serotype was prepared in SerasubH with 5%
protease-free BSA fraction V, 0.1% sodium azide, 50 mg/mL
gentamicin (SBAG) from 512 ng/mL to 0.5 ng/mL, in triplicate.
For native NS1, culture supernatants from Vero cells infected with
DENV serotype 1 (East Timor isolate, Genbank ID ET00243),
serotype 2 (New Guinea C isolate 1944), serotype 3 (East Timor
isolate, Genbank ID ET00209) or serotype 4 (East Timor isolate,
Genbank ID ET288) were harvested at days 3–5 or 7–10 post-
infection, depending on the multiplicity of infection and serotype.
The concentration of NS1 in the supernatants was estimated using
a quantitative ELISA [13]. A serial two-fold dilution of
supernatants was prepared in SBAG. SBAG alone was included
as a blank. Assays were performed as per the instructions for use.
Briefly, 50 mL of sample was added to a tube followed by 25 mLo f
Running Buffer and 25 mL of colloidal gold conjugated to an anti-
NS1 monoclonal antibody. After mixing, a test strip was added to
the tube and incubated for 15 min at RT. The absorbance of the
test line was measured using a Hamamatsu MS1000 strip reader.
Absorbance data was plotted and analysed using GraphPad Prism
4 software version 4.03. The limit of detection for each serotype
was determined as the concentration required to produce an
absorbance value of 8.5 mABS units (cut-off for visualisation of test
line) by interpolation from a polynomial non-linear regression.
Clinical evaluation sites and samples
The Dengue Early Rapid test was independently evaluated
alone or in combination with the Dengue Duo Cassette in
retrospective studies at two Southeast Asian sites. Commercial tests
were provided by Alere, Australia and testing was performed as
outlined in the instructions for use of the test. For both sites the
operators involved in the testing were experienced laboratory
technicians working in ISO15189 accredited diagnostic laborato-
ries. All operators received formal training in the methods and in
their interpretation and were blinded to the final reference
diagnosis.
An evaluation of the Dengue Early Rapid was conducted at the
Oxford University Clinical Research Unit in Vietnam using stored
acute plasma samples from 100 clinically suspected dengue
patients but with no laboratory evidence of acute or recent
dengue virus infection and 198 samples from patients with
laboratory-confirmed dengue. Samples were collected as part of
a prospective hospital-based study of early dengue in Dong Thap
Hospital, Dong Thap, Vietnam. The median age was 10 yrs
(range 3–15 yrs) and all patients provided written informed
consent to participate in the study. The study was approved by
the Dong Thap Hospital Ethical Committee and the Oxford
Tropical Research Ethical Committee. Plasma samples used in the
Dengue Early Rapid evaluation were collected from patients 1–4
days post-onset of dengue-like symptoms. Laboratory-confirmed
cases were defined by the detection of DENV RNA in plasma by
RT-PCR [16] or seroconversion in the IgM or IgG antigen-
capture ELISA [17] in a patient for whom there was a clinical
suspicion of dengue (see Figure S1A for the testing algorithm used
at Vietnam study site). A ‘‘not dengue’’ case was defined by the
absence of virological or serological evidence of DENV infection
in a patient where two paired plasma specimens were available
with the 2nd specimen taken a minimum of 2 days after the first
and at least 5 days after the onset of illness (Figure S1A). Reference
testing was performed 6 months prior to the evaluation of the
rapid test. The vast majority of the samples from this panel were
collected on day 3 post-onset of illness (59.4%), with 13.8%
collected on day 2, 12.1% on day 4 and only 2.7% from day 1. In
12% of the samples information on the day of collection was
unavailable (Table 1).
A second retrospective study of the Dengue Early Rapid used in
combination with the Dengue Duo Cassette was performed at the
University in Malaya. Positive specimens were obtained from a
dengue surveillance study conducted at the University of Malaya
Medical Centre (UMMC) from 2005 to 2008 and were selected to
represent a broad spectrum of patient presentation from 1–15 days
post-onset of illness. The study was approved the UMMC
Scientific and Ethics Committee. The median age of the patients
from this study was 25 yrs (range 1–67 yrs). The serum panel
included 263 samples laboratory-confirmed as positive for dengue
infection and 30 dengue negative samples from patients diagnosed
with an alternative illness, including Epstein-Barr Virus (n=10),
Cytomegalovirus (n=10) and BK virus (n=10) aetiologies.
Specimens were collected and tested for dengue using a
combination of virus isolation [18], haemagglutination inhibition
[19], RT-PCR [20], IgM capture ELISA [21], IgG capture
ELISA [22] and NS1 Capture ELISA [23] and were considered
positive if confirmed by two or more testing methods (see Figure
S1B for the testing algorithm used at Malaysia study site).
Table 1. Human serum panel in Vietnamese study site (n=298).
Days post-onset of illness RT-PCR Serotyping Serology{ Negative Total
DENV-1 DENV-2 DENV-3 DENV-4
1 10102 4 8
2 94504 1 94 1
36 0 { 14 20 2 22 59 177
4 1 3 6318 5 3 6
UNKNOWN* 18 0203 1 33 6
Total 101 24 31 3 39 100 298
{One sample was positive for both DENV-1 and DENV-2 by RT-PCR
{Negative by RT-PCR and Positive by IgG and IgM ELISA
*No information was available for day post-onset of illness that specimen was taken.
doi:10.1371/journal.pntd.0001199.t001
Combined Approach to Enhance Dengue Rapid Test
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evaluation of the two rapid tests. Negative cases were collected
from a routine diagnostic service provided by the University of
Malaya and were confirmed as dengue negative by the absence of
antibodies and NS1 (Figure S1B). No information on patient age
was available from the negative collection.
Statistical analysis
All statistical analysis was performed using SPSS version 12.0.1.
Clinical data was expressed with 95% confidence intervals.
Clinical sensitivity between groups were compared by Fisher’s
exact test (two-sided) and was considered significant if P,0.05.
Results
Binding kinetics and specificity of anti-NS1 monoclonal
antibodies used for antigen capture
The binding affinities of anti-NS1 antibodies (Ab1, Ab2 and
Ab3) used in the Dengue Early Rapid were determined by SPR.
Anti-NS1 antibodies were bound to a SPR sensor surface using the
capture method as described in the Methods section. The Ab2
antibody specifically bound to DENV1 and DENV2 NS1 with no
significant binding observed for DENV3 or DENV4. The Ab1
MAb effectively bound three of the four serotypes of NS1 with no
detectable binding to DENV1. Lastly, the Ab3 MAb was observed
to cross-react with all four NS1 serotypes.
In order to promote monovalent binding interactions that
facilitated facile determination of affinity and Langmuir binding
(analysis of binding kinetics), we decreased the capture level of
anti-NS1 antibodies to 50–70 RU. As a result, acceptable fitting of
the data could be obtained by the monovalent binding algorithm
(Figure 1). The dissociation rate constants ka, kd and KD derived
from a 1:1 binding model are reported in Table 2. The analysis
revealed that the ka values of the three MAbs were similar for all
recognised Dengue NS1 antigens, with the exception of Ab2 for
DENV1, which had a 2–3 fold faster on-rate than the others.
We observed that the kd values of the three MAbs were also
comparable with the exception of Ab1 for DENV3, which had a
faster dissociation rate than the others.
On the basis of this specificity data the Dengue Early Rapid test
was developed using an equimolar combination of Ab2 and Ab1
MAbs immobilised onto nitrocellulose membrane with the cross-
reactive Ab3 MAb conjugated to colloidal gold particles for
detection of captured NS1. The ability of the test to detect all four
serotypes of NS1 was verified by assessing the theoretical limits of
detection.
Limit of detection for each dengue NS1 serotype
The analytical sensitivity of the Dengue Early Rapid was
determined using recombinant NS1 of each four serotypes to be
,5 ng/mL, with a limit of detection of 0.75 ng/mL for DENV-1,
0.25 ng/mL for DENV-2, 3.5 ng/mL for DENV-3 and 2.4 ng/
mL for DENV-4 NS1 (Figure 2). The limit of detection for NS1
secreted from dengue-infected Vero cells was comparable to the
recombinant proteins with 4.4 ng/mL for DENV-1, 1.4 ng/
mL for DENV-2, 5.2 ng/mL for DENV-3 and 1.5 ng/mL for
DENV-4.
Clinical performance of Dengue Early Rapid test at
Vietnam study site
When compared to the 198 laboratory-confirmed dengue cases,
as indicated by the detection of viral RNA by RT-PCR and/or
seroconversion by IgM and IgG capture ELISA, the Dengue Early
Rapid had a sensitivity of 69.2% (95% CI: 62.8–75.6) (Table 3). In
the 159 of 198 samples that were positive by RT-PCR, the
sensitivity of the rapid test was marginally higher with NS1
detected in 71.1% of cases (95% CI: 64.0–78.1). Conversely, in
samples that demonstrated seroconversion with no viral RNA
detected (39 of 198) the sensitivity of the rapid test was lower, with
NS1 detected in 61.5% (95% CI: 46.2–76.8). The specificity of the
rapid test was 96% (95% CI: 92.2–99.8), with four false positives
observed from the panel of 100 endemic non-dengue specimens
(Table 3). When the performance of the NS1 rapid test format was
directly compared to an NS1 capture ELISA (BioRad Platelia), the
rapid was found to have a lower sensitivity, with 69.2% versus
83.8% respectively, but showed equivalent specificity.
Figure 1. Representative sensorgrams for binding of monoclo-
nal antibody Ab3 and DENV-1 NS1. Increasing concentrations of
dengue-1 NS1 were sequentially injected onto 70 RU of Ab3 captured
by anti-mouse IgG. The reference-subtracted data (black curve) were
fitted using 1:1 binding algorithm (red curve).
doi:10.1371/journal.pntd.0001199.g001
Table 2. Binding kinetics of anti-NS1 MAbs to dengue NS1
antigens determined by 1:1 binding model.
Anti-NS1
mAb
NS1
antigen
ka [M
21s
21]
610
4
kd [s
21]
610
24 KD [nM]
Ab1 DENV1 NS1 N/A N/A N/A
DENV2 NS1 2.160.04 2.460.06 11.560.5
DENV3 NS1 1.660.20 14.864.9 96.564.3
DENV4 NS1 2.160.02 1.160.05 51.062.1
Ab2 DENV1 NS1 4.860.05 2.5960.04 5.460.1
DENV2 NS1 2.860.06 3.5460.03 12.360.2
DENV3 NS1 N/A N/A N/A
DENV4 NS1 N/A N/A N/A
Ab3 DENV1 NS1 1.460.03 1.660.03 11.960.5
DENV2 NS1 1.960.01 1.360.04 6.960.2
DENV3 NS1 1.160.02 4.760.02 41.661.1
DENV4 NS1 1.260.00 3.760.07 31.260.6
KD was calculated by kd/ka. Values are mean 6 standard deviation from at least
three experiments.
doi:10.1371/journal.pntd.0001199.t002
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population of positive samples, DENV-1 was the predominant
serotype with 62.8% of PCR-confirmed samples with fewer
DENV-3 (19.5%), DENV-2 (15.9%) and DENV-4 (1.9%) cases
(Table 1). The sensitivity of the antigen rapid test for each serotype
was 78% for DENV-1, 62.5% for DENV-2, 61.3% for DENV-3
and 33.3% (1/3) for DENV-4.
Clinical performance of a combined antigen and
antibody testing protocol at Malaysia study site
At the Malaysia study site the predominant serotype was also
DENV-1 with 62.7% of PCR-confirmed samples with 14.3%
DENV-3, 13% DENV-2 and less than 10% DENV-4 (Table 4). Of
the 161 PCR positive samples tested at the Malaysia site, 111
produced a positive result on the Dengue Early Rapid for a
sensitivity of 68.9% (95% CI: 61.8 – 76.1). The relative sensitivity of
the NS1 rapid test for each serotype was 69.3% for DENV-1, 62%
for DENV-2, 78.3% for DENV-3 and 62.5% for DENV-4. NS1
antigen was also detected in 51% of positive samples that were RT-
PCR negative but positive by serology. The sensitivity of the NS1
rapid was found to be slightly lower than an NS1 capture ELISA
(PanbioH Dengue Early ELISA). The ELISA had a sensitivity of
68.4% against confirmed acute dengue samples compared to 62%
for the rapid test. This was mirrored in the performance compared
to RT-PCR positive samples with the ELISA having a sensitivity of
78.3% compared to 68.9% for the rapid.
A small number of dengue negative samples that were
characterised as positive for other viral aetiologies were included
as specificity controls. Of the 30 dengue negative samples tested,
the NS1 rapid test had a specificity of 96.7% (95% CI: 82.8 – 99.9)
with one false positive result observed. The problematic sample
was collected from a patient infected with Cytomegalovirus
(CMV).
The Malaysia study assessed the clinical utility of using the
Dengue Early Rapid alone and in combination with the Dengue
Duo Cassette (Figure 3). As individual tests the sensitivity of the
Dengue Early Rapid and Dengue Duo Cassette was 62.0% and
72.5% respectively. The combination of NS1 detection with anti-
IgM detection resulted in a significant (P,0.001) increase in
sensitivity to 89.0% (95% CI: 85.2 – 92.8) compared to detection
of NS1 alone (Figure 3), with the caveat that a single IgM positive
test provides a presumptive, not confirmatory, diagnosis. Sensitiv-
Figure 2. Analytical sensitivity of Dengue Early Rapid test for recombinant dengue NS1. The test line signal intensity was measured
against a serial two-fold dilution series of DENV-1 NS1 (A), DENV-2 NS1 (B), DENV-3 NS1 (C) and DENV-4 NS1 (D) from 512 ng/mL to 0.5 ng/mL. The
analytical limit of detection was determined as the lowest concentration required to produce a positive result of 8.5 mABS (absorbance) units using
interpolation from a non-linear regression. An absorbance value of 8.5 mABS was determined to be the cut-off value for visualisation of the test line.
doi:10.1371/journal.pntd.0001199.g002
Table 3. Accuracy of Dengue Early Rapid (NS1) test in
Vietnamese study site.
Samples n Dengue Early Rapid
agreement % 95% CI
Positive 198 137 69.2 62.8 – 75.6
Negative 100 96 96.0 92.2 – 99.8
doi:10.1371/journal.pntd.0001199.t003
Combined Approach to Enhance Dengue Rapid Test
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markers (NS1, anti-IgM and anti-IgG); however the higher
sensitivity was offset by a slight loss of specificity.
The sensitivity of the antigen and antibody rapid tests at each
day post-onset of illness highlighted the clear difference between
the windows of detection between the two tests (Figure 4). As
expected, the antigen rapid test had greater sensitivity early in the
course of infection, with a peak sensitivity of 75% at days 2 and 3.
NS1 sensitivity decreased from day 3 onwards and coincided with
the rise in detection of antibodies. From day 6 the IgM/IgG rapid
test showed .95% sensitivity.
Discussion
In this study we report on the performance of a new commercial
rapid test for dengue NS1, evaluated at two Southeast Asian study
sites. The test was developed using a combination of monoclonal
antibodies capable of detecting all four serotypes of the antigen at
low ng/mL concentrations. This promising analytical sensitivity
Table 4. Human serum panel from Malaysian study site (n=293).
Days post-onset
of illness (DOI) RT-PCR
Virus
Isolation
IgM Capture
ELISA Negative
Total
each DOI
DENV-1 DENV-2 DENV-3 DENV-4
1 10244 0 0 8
2 72354 2 0 2 0
3 28 4 8 1 13 24 0 45
43 5 5 3 4 7 3 2 0 6 0
52 2 7 4 2 1 4 2 0 5 0
6 23201 2 8 0 2 9
7 00100 2 1 0 2 1
8 60000 9 0 9
9 00000 2 0 2
1 0 00000 1 0 1
1 1 00000 3 0 3
1 2 00000 7 0 7
1 3 00000 6 0 6
1 4 00000 1 0 1
1 5 00000 1 0 1
UNKNOWN* 0 0 0 0 0 0 30 30
Total 101 21 23 16 30 179 30
*No information was available for day post-onset of illness that negative specimens were collected.
doi:10.1371/journal.pntd.0001199.t004
Figure 3. Accuracy of dengue rapid tests at the Malaysian
study site. Diagnosis was confirmed using a combination of HI, virus
isolation, RT-PCR and IgM ELISA (n=293). Sensitivity (%) between
groups was compared using Fisher’s exact test.
doi:10.1371/journal.pntd.0001199.g003
Figure 4. Clinical sensitivity of rapid tests for acute dengue
over the course of illness. Data was obtained from laboratory-
confirmed cases of dengue at the Malaysian study site (n=263).
doi:10.1371/journal.pntd.0001199.g004
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sensitivity and specificity that was comparable to other commer-
cially available NS1 rapid tests evaluated in the same endemic
region [24]. Overall, we found that optimal diagnostic sensitivity
for acute dengue was achieved when NS1 testing was combined
with IgM and IgG detection, with a significant increase in
sensitivity compared to the outcome from using each individual
marker.
Despite NS1 becoming an established and very useful diagnostic
marker for early detection of acute dengue infection [11,18,23,25],
differences in the kinetics of its disappearance from the sera of
primary versus secondary infections means that caution should
always be exercised in interpreting findings based on NS1
detection alone. With the rapid rise of an anamnestic antibody
response to shared epitopes in secondary infections, NS1 levels
may be quickly masked by circulating antibody and/or cleared
from circulation. Hence, we and others [24,26] have shown that
the most effective diagnostic application of NS1 detection is when
it is combined with antibody detection. Together, they provide a
broader window of detection than was possible with traditional
antibody-based serological assays. Direct detection of viraemia by
RT-PCR shares a similar window of detection to the presence of
NS1. However it has become apparent that there is not a precise
correlation between the two markers, with NS1 often detected in
the absence of RNA and vice versa [10,27–29]. Although
originally viewed as a surrogate marker for viraemia, circulating
levels of NS1 are more likely a measure of infected cell mass.
Degradation and/or clearance from circulation of these two
infected cell products are also likely to vary [17].
Data from this study supports a growing body of evidence that a
combination of NS1 and IgM/IgG detection provides increased
diagnostic sensitivity. As individual tests the sensitivity of the
Dengue Early Rapid and Dengue Duo Cassette was 62% and
72.5%, respectively, but when used together the sensitivity was
increased to 93%. The two tests have complementary windows of
detection and we observed a gradual improvement in sensitivity
from as early as day 2 post-onset of illness with the combined
antigen and antibody approach. Tricou et al.[24] recently
compared the performance of two other commercial NS1 rapid
tests and identified that combined NS1 and IgM/IgG testing
increased the overall test sensitivity without reducing specificity.
However unlike the Tricou study we observed a reduced specificity
with the combined Panbio tests, with the majority of false positives
arising from the IgM/IgG rapid assay. However, considering the
specificity of our combined antigen and antibody testing approach
was determined based on a very small number (n=30) of
potentially cross-reactive samples and that there have been
contrasting reports of dengue IgM and IgG ICTs having either
very good specificity of .95% [30] or more moderate specificity
[31,32], an expanded study with a larger population of endemic
negative samples will be required to more accurately assess the
overall impact on specificity by combining both tests.
In both the Vietnam and Malaysia evaluations, the dengue
positive population was heavily skewed towards DENV-1 infection
with much lower proportions of DENV-2, DENV-3 and DENV-4
infections. Although an equivalent analytical sensitivity has been
demonstrated for all four serotypes, these theoretical limits of
detection were established using recombinant proteins developed
using gene sequences from East Timor, New Guinea and Puerto
Rican clinical isolates and may not account for subtle variations in
linear or conformational epitopes between strains. Additional
clinical data will be needed from populations in which DENV-2,
DENV-3 and DENV-4 infections are predominant in order to
validate the utility of the test during outbreaks of each serotype.
Demonstrating good clinical sensitivity for DENV-2 infections will
be relevant considering reports that the concentration of NS1 in
serum may be lower relative to DENV-1 and DENV-3 infections
[11,17]. There have also been reports of reduced sensitivity
towards DENV-3 with other rapid NS1 tests [33,34]. It will also be
important to validate the performance of the combined dengue
NS1 and IgM/IgG testing in other dengue endemic regions such
as the Americas, Pacific Islands, India and Africa.
The ongoing challenge for dengue serological assays surrounds
the need for sensitivity towards all four related, but antigenically
distinct, serotypes whilst at the same time limiting unwanted cross-
reactivity to other members of the flaviviridae family that co-
circulate in dengue endemic regions, such as Japanese Enceph-
alitis, and Yellow Fever. There is scope to improve on assay
sensitivity with the development of improved recombinant
antigens and capture antibodies with faster on-rates, which are
in progress. False positivity can occur as a result of cross-reactive
antibodies from a previous flavivirus infection and auto-immune
complexes [2]. NS1 has been recognised as a highly specific
serological marker and provides an expanded window of detection
when included with traditional antibody detection. Tricou et al
[24] and Hang et al [11] have observed 100% specificity using the
BioRadH NS1 rapid test in clinical evaluations in Vietnam and in
these clinical studies we have observed .95% specificity with the
Dengue Early Rapid test. The very high specificity of these tests
combined with their early window of detection and ease of use
make them an ideal candidate for use as a surveillance tool.
In conclusion, we have demonstrated that the PanbioH Dengue
Early Rapid is both a sensitive and specific rapid test for dengue
NS1. When used in combination with an IgM/IgG rapid test a
significant increase in sensitivity for acute dengue was observed
with the added benefit of an extended window of detection. The
use of rapid ICTs for dengue has become increasingly popular,
particularly in developing countries, due to their simplicity,
affordability and their suitability for use at or near the point of
care. The availability of NS1 to complement antibody detection
further enhances the clinical utility of this platform. At both study
sites, the predominant infecting serotype was DENV-1 and
ongoing clinical evaluation of this combined antigen and antibody
testing protocol will be required during outbreaks with other
serotypes as well as in other endemic regions outside of Southeast
Asia. The focus of this investigation was improved sensitivity of
dengue diagnosis but there is also a need to more comprehensively
evaluate the effect of this combined approach on specificity and
ultimately positive predictability.
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